Loading data for GANX — first visit, this takes a few seconds.

Preisalarm

Gain Therapeutics Inc. (GANX)

NasdaqGM: GANX · Echtzeitkurs · USD

2.17

+0.05 (2.36%)

Zum Schluss: Aug 18, 2026, 8:00 PM

2.36% (1D)

Keine Daten verfügbar

Geld	1.28
Marktkapitalisierung	88.6 Mio
Umsatz (TTM)	n/a
Nettogewinn (TTM)	-20.11 Mio
Beta	0.20
EPS (ttm)	-0.5
KGV (TTM)	n/a
Forward-KGV	-3.74
KBV (TTM)	4.60
KUV (TTM)	n/a
Earnings Date	n/a

Brief	2.27
Volumen	1,327,502
Ø Vol. (20D)	896,577
Eröffnung	2.15
Vortagesschluss	2.12
Tagesspanne	2.13 - 2.37
52-Wk Range	1.51 - 4.34
Analyst	n/a
Kursziel	n/a
Dividenden	n/a
Ex-Dividenden-Datum	n/a

Über GANX

Gain Therapeutics, Inc., a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas in Switzerland, Spain, the United States, and Australia. The company's drug discovery platform Magellan discovers novel allosteric binding sites in a disease; identifies proprietary small molecules that bind these sites to modulate protein function; and treats the underlying cause of the disease. Its lead...

[Mehr lesen]

Branche Biotechnology

Sektor Healthcare

IPO Datum Mar 19, 2021

Mitarbeiter 20

Börse NasdaqGM

Tickersymbol GANX

Website https://gaintherapeutics.com

Vollständiges Unternehmensprofil

Finanzielle Entwicklung

Im Jahr 2025 betrug der Umsatz von Gain Therapeutics 0, ein Anstieg von undefined% im Vergleich zum Vorjahr (0). Der Gewinn lag bei -20.16 Mio, ein Rückgang von -1.23 %.

Finanzberichte

Gewinnüberraschung

Gain Therapeutics hat die Quartalszahlen am Aug 11, 2026 veröffentlicht:

Umsatz von $0 verfehlt die Erwartungen um $0, mit NaN% Wachstum im Jahresvergleich.

EPS von -0.11 übertrifft die Erwartungen um 0.04, mit 42.11% Wachstum im Jahresvergleich.

Nachrichten

vor 1 Monat · Stocktwits

Why Is GANX Stock Rallying 22% After Hours?

The U.S. Food and Drug Administration (FDA) cleared Gain Therapeutics to begin a mid-stage clinical trial of its experimental drug GT-02287 in people with Parkinson’s disease.

vor 2 Monaten · Simply Wall St.

Gain Therapeutics expands ‘compelling’ evidence base for Parkinson’s candidate

Gain Therapeutics’ Parkinson’s candidate GT-02287 showed durable clinical stability and biomarker improvements in extended Phase 1b data.

vor 2 Monaten · Simply Wall St.

3 Parkinson's Biotech Stocks Analysts Think Are Wildly Mispriced

Most biotech stocks working towards a treatment for Parkinson's are already carrying a premium price. These three sit further off the radar, and analysts think the market has them badly wrong.

vor 3 Monaten · InvestorsHub

Gain Therapeutics (GANX) Shares Edge Higher After Narrower-Than-Expected Q1 Loss

Gain Therapeutics, Inc. (NASDAQ:GANX) shares rose 3.

vor 3 Monaten · Simply Wall St.

3 US Biotechs Developing Parkinson’s Therapies

Global markets may be dealing with inflation, shifting rate expectations, and energy volatility, but companies tackling long-term health challenges like Parkinson’s disease are still pushing ahead.

Seite 1 von 2

Gain Therapeutics Inc. (GANX)